Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Current Assets: 2009-2025

Historic Current Assets for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Sep 2025 value amounting to $3.5 billion.

  • UNITED THERAPEUTICS's Current Assets fell 12.66% to $3.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 billion, marking a year-over-year decrease of 12.66%. This contributed to the annual value of $3.9 billion for FY2024, which is 9.09% up from last year.
  • As of Q3 2025, UNITED THERAPEUTICS's Current Assets stood at $3.5 billion, which was down 8.70% from $3.8 billion recorded in Q2 2025.
  • In the past 5 years, UNITED THERAPEUTICS's Current Assets ranged from a high of $4.0 billion in Q3 2024 and a low of $2.0 billion during Q1 2021.
  • For the 3-year period, UNITED THERAPEUTICS's Current Assets averaged around $3.6 billion, with its median value being $3.6 billion (2023).
  • Its Current Assets has fluctuated over the past 5 years, first skyrocketed by 45.48% in 2022, then dropped by 12.66% in 2025.
  • UNITED THERAPEUTICS's Current Assets (Quarterly) stood at $2.3 billion in 2021, then surged by 45.48% to $3.4 billion in 2022, then increased by 5.05% to $3.6 billion in 2023, then increased by 9.09% to $3.9 billion in 2024, then declined by 12.66% to $3.5 billion in 2025.
  • Its last three reported values are $3.5 billion in Q3 2025, $3.8 billion for Q2 2025, and $3.9 billion during Q1 2025.